Piper Sandler analyst Adam Maeder lowered the firm’s price target on Nevro to $37 from $38 and keeps an Underweight rating on the shares. The analyst updated models in medical technology and devices to reflect recent company updates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO: